Trial Profile
Phase II Study Evaluating the Combination of Everolimus and Sorafenib in the Treatment of Thyroid Cancer.
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 21 Jul 2023
Price :
$35
*
At a glance
- Drugs Everolimus (Primary) ; Sorafenib (Primary)
- Indications Carcinoma; Thyroid cancer
- Focus Therapeutic Use
- 18 Jul 2023 Planned End Date changed from 1 Jun 2023 to 1 Jun 2025.
- 18 Jul 2023 Planned primary completion date changed from 1 Jun 2023 to 1 Jun 2025.
- 01 Jul 2022 Planned End Date changed from 1 Jun 2022 to 1 Jun 2023.